NYSE: GKOS · Medical Devices
Glaukos (GKOS) fair value: undervalued or overvalued?
As of 29 Sep 2026, Faircurve's model values Glaukos (GKOS) at $147.85 a share. The stock last closed at $163.75, which puts the model's fair value 9.7% below the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 2 Oct 2026. Glaukos Corporation.
Faircurve Insights · 29 Sep 2026
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases.
On 29 Sep 2026, Faircurve's model found a fair value of $147.85 a share. The previous run, on 26 Sep 2026, gave $144.00, meaning the fair value moved +2.7%. The model's calibrated range over 63 trading days is $124.04 to $180.28, which held the price 60% of the time at this horizon, and the evidence grade is Medium.
The overall quality score against comparable companies is 55 out of 100, with a Profitability score of 5 and Growth quality of 91. The model compares it with Insulet Corp. (PODD), Bruker Corporation (BRKR), Globus Medical, Inc. (GMED), Bio-Rad Laboratories, Inc. (BIO), Align Technology, Inc. (ALGN), Penumbra, Inc. (PEN), Haemonetics Corporation (HAE), and Zimmer Biomet Holdings, Inc. (ZBH). The median move around the last 8 earnings reports was 10.9%.
Written from the figures on this page for the 29 Sep 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give GKOS?
The calibrated range for GKOS over 63 trading days is $124.04 to $180.28. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,327 past valuations, refreshed 26 Sep 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $111.64 to $190.43. In 41% of the simulations the fair value came out above the price the model ran on.
How does GKOS score on business quality?
Glaukos's overall quality score is 55 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 5 | -11.7%ROIC | 2.9% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 100 | ||
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analyst estimate revisions. | 91 | 32.3%Revenue growth, trailing | 10.0% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 75 | 0.0%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 56 | 0.08xNet debt / EBITDA | 1.35x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 17 | 5.6 ptsEBITDA margin downside volatility, 5y | 2.4 pts |
How does GKOS compare with similar companies?
The companies in medical devices closest to Glaukos in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| PODD Insulet Corp. | $131.69 | $142.34 | +8.1% | Fairly valued |
| BRKR Bruker Corporation | $63.24 | $68.13 | +7.7% | Fairly valued |
| GMED Globus Medical, Inc. | $75.60 | $74.08 | -2.0% | Fairly valued |
| BIO Bio-Rad Laboratories, Inc. | $369.14 | $330.73 | -10.4% | Fairly valued |
| ALGN Align Technology, Inc. | $143.74 | $178.60 | +24.3% | Undervalued |
| PEN Penumbra, Inc. | $317.55 | $285.08 | -10.2% | Fairly valued |
| HAE Haemonetics Corporation | $104.68 | $106.81 | +2.0% | Fairly valued |
| ZBH Zimmer Biomet Holdings, Inc. | $88.29 | $109.35 | +23.9% | Undervalued |
When does GKOS report earnings, and how has the stock reacted?
Glaukos's next earnings report is scheduled for 4 Nov 2026. Companies can move their dates.
Options prices on 2 Oct 2026 imply a move of about 9.0% in either direction through the nearest expiry, about 13 days out. That is the size the market is pricing, not a direction.
How GKOS moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 10.9%.
| Report date | Two session move |
|---|---|
| 29 Jul 2026 | +11.4% |
| 29 Apr 2026 | +20.1% |
| 17 Feb 2026 | +10.5% |
| 29 Oct 2025 | +12.9% |
| 30 Jul 2025 | -8.2% |
| 30 Apr 2025 | +7.1% |
| 20 Feb 2025 | -21.6% |
| 4 Nov 2024 | -3.0% |
Glaukos at a glance
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases.
- Market value
- $9.1B
- Sector
- Healthcare
- Industry
- Medical Devices
- Revenue expected, next twelve months
- $806M
- Consensus revenue growth, next fiscal year
- +36.2%
- Analysts with estimates
- 9
- Beta to the US market
- 0.79
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Glaukos on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 26 Sep 2026 the model's fair value for GKOS was $144.00. As of 29 Sep 2026 it is $147.85, a change of +2.7%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Glaukos's valuation
Is Glaukos stock undervalued or overvalued?
On Faircurve's model, GKOS reads as Fairly valued as of 29 Sep 2026. The model's fair value is $147.85 a share against a last close of $163.75, a gap of -9.7%.
What is GKOS's fair value?
$147.85 a share as of 29 Sep 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $111.64 to $190.43.
What price range does the model give GKOS?
$124.04 to $180.28 over 63 trading days. Ranges built this way held the price 60% of the time across 4,327 past valuations, refreshed 26 Sep 2026.
When does Glaukos report earnings next?
The next report is scheduled for 4 Nov 2026. Companies can move their dates.
How much has GKOS moved on past earnings reports?
Across its last 8 reports the median two session move was 10.9%, ignoring direction. The largest was -21.6% around the report of 20 Feb 2025.
How confident is the model in this valuation?
The model's evidence grade for GKOS is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.